sur GENEURO SA (EPA:GNRO)
GeNeuro Announces Unanimous Approval of Resolutions at AGM
Geneva, Switzerland, June 14, 2024 – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company, revealed that all resolutions proposed at its Annual General Meeting (AGM) held on June 12, 2024, have been unanimously approved. A significant 81.54% of the company’s share capital was represented at the meeting.
Key resolutions included approving the annual report and year-end accounts for 2023, re-electing the Chairman and all Board members, approving the maximum aggregate compensation for the Board and management for 2025, and re-electing PricewaterhouseCoopers, Geneva, as auditors. Detailed results are available on the company's website.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENEURO SA